186 related articles for article (PubMed ID: 23102192)
1. [BRAF mutation: a novel approach in targeted melanoma therapy].
Arenbergerová M; Puzanov I
Klin Onkol; 2012; 25(5):323-8. PubMed ID: 23102192
[TBL] [Abstract][Full Text] [Related]
2. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
3. Novel therapies in melanoma.
Scheier B; Amaria R; Lewis K; Gonzalez R
Immunotherapy; 2011 Dec; 3(12):1461-9. PubMed ID: 22091682
[TBL] [Abstract][Full Text] [Related]
4. Upcoming strategies for the treatment of metastatic melanoma.
Spagnolo F; Queirolo P
Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184
[TBL] [Abstract][Full Text] [Related]
5. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
6. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
7. Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
Peters S; Bouchaab H; Zimmerman S; Bucher M; Gaide O; Letovanec I; Homicsko K; Michielin O
Melanoma Res; 2014 Oct; 24(5):496-500. PubMed ID: 25185693
[TBL] [Abstract][Full Text] [Related]
8. Melanoma brain metastasis: overview of current management and emerging targeted therapies.
Fonkem E; Uhlmann EJ; Floyd SR; Mahadevan A; Kasper E; Eton O; Wong ET
Expert Rev Neurother; 2012 Oct; 12(10):1207-15. PubMed ID: 23082737
[TBL] [Abstract][Full Text] [Related]
9. Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.
Heakal Y; Kester M; Savage S
Ann Pharmacother; 2011 Nov; 45(11):1399-405. PubMed ID: 22028422
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
11. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
Martin-Liberal J; Larkin J
Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114
[TBL] [Abstract][Full Text] [Related]
12. Melanoma: diagnosis, staging, and treatment. Consensus group recommendations.
Berrocal A; Cabañas L; Espinosa E; Fernández-de-Misa R; Martín-Algarra S; Martínez-Cedres JC; Ríos-Buceta L; Rodríguez-Peralto JL
Adv Ther; 2014 Sep; 31(9):945-60. PubMed ID: 25145549
[TBL] [Abstract][Full Text] [Related]
13. Vemurafenib: in unresectable or metastatic melanoma.
Keating GM
BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
[TBL] [Abstract][Full Text] [Related]
14. BRAF-Targeted Therapy to Treat Superior Vena Cava Syndrome in a Patient With Metastatic Cancer.
Mesko SM; Rosenthal KJ; Boasberg PD; Hamid O
J Clin Oncol; 2015 Sep; 33(25):e101-3. PubMed ID: 24711550
[No Abstract] [Full Text] [Related]
15. Vemurafenib for the treatment of melanoma.
Jordan EJ; Kelly CM
Expert Opin Pharmacother; 2012 Dec; 13(17):2533-43. PubMed ID: 23094782
[TBL] [Abstract][Full Text] [Related]
16. Vemurafenib in melanoma.
Shaw HM; Nathan PD
Expert Rev Anticancer Ther; 2013 May; 13(5):513-22. PubMed ID: 23617343
[TBL] [Abstract][Full Text] [Related]
17. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
Seeley AR; De Los Santos JF; Conry RM
Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
[TBL] [Abstract][Full Text] [Related]
18. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A
N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494
[TBL] [Abstract][Full Text] [Related]
19. Vemurafenib beyond progression in a patient with metastatic melanoma: a case report.
Grimaldi AM; Simeone E; Palla M; Festino L; Caracò C; Mozzillo N; Petrillo A; Muto P; Ascierto PA
Anticancer Drugs; 2015 Apr; 26(4):464-8. PubMed ID: 25622086
[TBL] [Abstract][Full Text] [Related]
20. Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.
Seremet T; Lienard D; Suppa M; Trepant AL; Rorive S; Woff E; Cuylits N; Jansen Y; Schreuer M; Del Marmol V; Neyns B
Melanoma Res; 2015 Apr; 25(2):180-3. PubMed ID: 25643238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]